PharMerica Co. (PMC) Given Average Rating of “Hold” by Brokerages
Shares of PharMerica Co. (NYSE:PMC) have received an average recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $29.25.
PMC has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of PharMerica from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. ValuEngine raised shares of PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st.
In related news, CEO Gregory S. Weishar sold 521,089 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $29.25, for a total value of $15,241,853.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 534,089 shares of company stock worth $15,243,073. 5.04% of the stock is owned by company insiders.
Shares of PharMerica (NYSE:PMC) opened at $29.25 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.58 and a debt-to-equity ratio of 0.79. The stock has a market cap of $910.27, a PE ratio of 47.95, a PEG ratio of 1.27 and a beta of 0.82. PharMerica has a fifty-two week low of $22.00 and a fifty-two week high of $29.50.
PharMerica (NYSE:PMC) last issued its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.03). The firm had revenue of $595.10 million during the quarter, compared to the consensus estimate of $596.80 million. PharMerica had a net margin of 0.54% and a return on equity of 2.30%. analysts predict that PharMerica will post 1.92 earnings per share for the current year.
PharMerica Company Profile
Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.